Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 8, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced it had received written notification from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement of $1.00 per ADS under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable cr

Related Keywords

Switzerland , Geneva , Genè , United States , Swiss , American , Mike Sinclair , Tim Dyer , Swiss Exchange , Nasdaq Stock Market , Nasdaq , Nasdaq Listing Rule , Addex Therapeutics , American Depositary Shares , Allosteric Modulator , Drug Discovery And Development , Saddex , Am , Drug Discovery ,